News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
711,564 Results
Type
Article (42157)
Company Profile (436)
Press Release (668971)
Section
Business (208672)
Career Advice (2021)
Deals (36001)
Drug Delivery (103)
Drug Development (83536)
Employer Resources (173)
FDA (16400)
Job Trends (15083)
News (352645)
Policy (33043)
Tag
2024 BioCapital Digital (10)
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (8)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (10)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (8)
2024 Genetown Standard (10)
2024 Lone Star Bio Digital (8)
2024 Pharm Country Digital (7)
2024 Pharm Country Standard (6)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (8)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (1)
Academia (2635)
Accelerated approval (3)
Adcomms (24)
Allergies (82)
Alliances (50888)
ALS (86)
Alzheimer's disease (1395)
Antibody-drug conjugate (ADC) (122)
Approvals (16387)
Artificial intelligence (241)
Autoimmune disease (16)
Automation (14)
Bankruptcy (371)
Best Places to Work (11841)
BIOSECURE Act (18)
Biosimilars (101)
Biotechnology (330)
Bladder cancer (61)
Brain cancer (24)
Breast cancer (252)
Cancer (2012)
Cardiovascular disease (158)
Career advice (1686)
Career pathing (29)
CAR-T (146)
Cell therapy (415)
Cervical cancer (17)
Clinical research (67440)
Collaboration (800)
Compensation (452)
Complete response letters (23)
COVID-19 (2640)
CRISPR (39)
C-suite (214)
Cystic fibrosis (103)
Data (1925)
Decentralized trials (2)
Denatured (26)
Depression (44)
Diabetes (246)
Diagnostics (6386)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (115)
Drug pricing (104)
Drug shortages (26)
Duchenne muscular dystrophy (90)
Earnings (87358)
Editorial (35)
Employer branding (21)
Employer resources (147)
Events (115110)
Executive appointments (642)
FDA (17507)
Featured Employer (55)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (716)
Gene editing (102)
Generative AI (19)
Gene therapy (295)
GLP-1 (716)
Government (4465)
Grass and pollen (4)
Guidances (48)
Healthcare (19134)
Huntington's disease (23)
IgA nephropathy (24)
Immunology and inflammation (112)
Indications (27)
Infectious disease (2771)
Inflammatory bowel disease (138)
Inflation Reduction Act (11)
Influenza (47)
Intellectual property (84)
Interviews (311)
IPO (16766)
IRA (43)
Job creations (3699)
Job search strategy (1434)
Kidney cancer (9)
Labor market (34)
Layoffs (477)
Leadership (16)
Legal (7976)
Liver cancer (71)
Lung cancer (293)
Lymphoma (131)
Machine learning (2)
Management (58)
Manufacturing (273)
MASH (62)
Medical device (13463)
Medtech (13468)
Mergers & acquisitions (19693)
Metabolic disorders (654)
Multiple sclerosis (69)
NASH (19)
Neurodegenerative disease (88)
Neuropsychiatric disorders (30)
Neuroscience (1890)
NextGen: Class of 2025 (6754)
Non-profit (4546)
Northern California (2413)
Now hiring (37)
Obesity (358)
Opinion (220)
Ovarian cancer (73)
Pain (79)
Pancreatic cancer (77)
Parkinson's disease (136)
Partnered (18)
Patents (202)
Patient recruitment (94)
Peanut (47)
People (58428)
Pharmaceutical (86)
Pharmacy benefit managers (19)
Phase I (21187)
Phase II (29761)
Phase III (22006)
Pipeline (984)
Podcasts (73)
Policy (115)
Postmarket research (2601)
Preclinical (9041)
Press Release (67)
Prostate cancer (94)
Psychedelics (37)
Radiopharmaceuticals (260)
Rare diseases (374)
Real estate (6008)
Recruiting (66)
Regulatory (22573)
Reports (46)
Research institute (2412)
Resumes & cover letters (351)
Rett syndrome (3)
RNA editing (2)
RSV (37)
Schizophrenia (69)
Series A (129)
Series B (83)
Service/supplier (11)
Sickle cell disease (54)
Southern California (2097)
Special edition (17)
Spinal muscular atrophy (152)
Sponsored (29)
Startups (3757)
State (2)
Stomach cancer (13)
Supply chain (60)
The Weekly (44)
United States (21401)
Vaccines (671)
Venture capitalists (38)
Webinars (13)
Weight loss (244)
Women's health (35)
Worklife (16)
Date
Today (27)
Last 7 days (576)
Last 30 days (2670)
Last 365 days (34516)
2025 (7847)
2024 (36301)
2023 (41015)
2022 (52276)
2021 (56763)
2020 (54920)
2019 (47416)
2018 (35696)
2017 (33024)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (735)
Alabama (54)
Alaska (7)
Arizona (231)
Arkansas (14)
Asia (39095)
Australia (6507)
California (5569)
Canada (1864)
China (476)
Colorado (251)
Connecticut (268)
Delaware (126)
Europe (85345)
Florida (813)
Georgia (190)
Idaho (57)
Illinois (506)
India (23)
Indiana (292)
Iowa (10)
Japan (140)
Kansas (103)
Kentucky (24)
Louisiana (8)
Maine (60)
Maryland (843)
Massachusetts (4253)
Michigan (210)
Minnesota (372)
Mississippi (2)
Missouri (76)
Montana (29)
Nebraska (25)
Nevada (56)
New Hampshire (66)
New Jersey (1579)
New Mexico (30)
New York (1583)
North Carolina (974)
North Dakota (7)
Northern California (2413)
Ohio (193)
Oklahoma (14)
Oregon (37)
Pennsylvania (1252)
Puerto Rico (9)
Rhode Island (27)
South America (1108)
South Carolina (18)
South Dakota (1)
Southern California (2097)
Tennessee (92)
Texas (828)
Utah (166)
Virginia (131)
Washington D.C. (59)
Washington State (525)
West Virginia (3)
Wisconsin (49)
711,564 Results for "neumora therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Depression
Neumora’s Novel Depression Drug Strikes Out in First Pivotal Trial
In a highly anticipated readout for the kappa opioid receptor class in major depressive disorder, Neumora’s navacaprant failed to meet the primary and key secondary endpoint in the first of three identical Phase III studies.
January 2, 2025
·
2 min read
·
Heather McKenzie
Depression
Neumora Shakes Up Phase III MDD Trials After January Miss
After failing to hit the primary endpoint in a Phase III trial, Neumora is remixing study parameters in two replicate trials, with data expected in the first half of 2026.
March 3, 2025
·
1 min read
·
Dan Samorodnitsky
Press Releases
Neumora Therapeutics to Present at Leerink Global Healthcare Conference
March 4, 2025
·
1 min read
Press Releases
Neumora Therapeutics Announces Leadership Transition
February 13, 2025
·
5 min read
Press Releases
Neumora Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 4, 2025
·
11 min read
Genetown
Neumora Therapeutics to Participate in Upcoming Conferences in May 2024
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, announced that the Company will participate in two investor conferences in May.
May 6, 2024
·
1 min read
Drug Development
Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer’s Disease Agitation
Neumora Therapeutics, Inc. (Neumora), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced the initiation of a Phase 1b study evaluating NMRA-511 for the treatment of agitation associated with dementia due to Alzheimer’s disease (AD).
June 20, 2024
·
8 min read
Press Releases
Neumora Therapeutics to Participate in Upcoming Conferences in November
November 6, 2024
·
1 min read
Business
Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Neumora Therapeutics, Inc. announced financial results for the first quarter ended March 31, 2024, and provided a business update.
May 7, 2024
·
9 min read
Press Releases
Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder
January 2, 2025
·
8 min read
1 of 71,157
Next